1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
Sung, H.; Ferlay, J.; Siegel, R.L.; Laversanne, M.; Soerjomataram, I.; Jemal, A.; Bray, F. Global Cancer Statistics 2020: GLOBOCAN
Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA A Cancer J. Clin. 2021, 71, 209–249. [CrossRef]
Litwin, M.S.; Tan, H.-J. The Diagnosis and Treatment of Prostate Cancer: A Review. JAMA 2017, 317, 2532–2542. [CrossRef]
[PubMed]
Wade, C.A.; Kyprianou, N. Profiling Prostate Cancer Therapeutic Resistance. Int. J. Mol. Sci. 2018, 19, 904. [CrossRef] [PubMed]
Kaszak, I.; Witkowska-Piłaszewicz, O.; Niewiadomska, Z.; Dworecka-Kaszak, B.; Ngosa Toka, F.; Jurka, P. Role of Cadherins in
Cancer—A Review. Int. J. Mol. Sci. 2020, 21, 7624. [CrossRef] [PubMed]
Du, B.; Shim, J.S. Targeting Epithelial–Mesenchymal Transition (EMT) to Overcome Drug Resistance in Cancer. Molecules 2016, 21,
965. [CrossRef]
Lamouille, S.; Xu, J.; Derynck, R. Molecular Mechanisms of Epithelial–Mesenchymal Transition. Nat. Rev. Mol. Cell Biol. 2014, 15,
178–196. [CrossRef]
Seruga, B.; Ocana, A.; Tannock, I.F. Drug Resistance in Metastatic Castration-Resistant Prostate Cancer. Nat. Rev. Clin. Oncol.
2011, 8, 12–23. [CrossRef]
Rose, M.; Burgess, J.T.; O’Byrne, K.; Richard, D.J.; Bolderson, E. PARP Inhibitors: Clinical Relevance, Mechanisms of Action and
Tumor Resistance. Front. Cell Dev. Biol. 2020, 8, 564601. [CrossRef]
Sreekumar, S.; Zhou, D.; Mpoy, C.; Schenk, E.; Scott, J.; Arbeit, J.M.; Xu, J.; Rogers, B.E. Preclinical Efficacy of a PARP-1 Targeted
Auger-Emitting Radionuclide in Prostate Cancer. Int. J. Mol. Sci. 2023, 24, 3083. [CrossRef]
Nicolosi, P.; Ledet, E.; Yang, S.; Michalski, S.; Freschi, B.; O’Leary, E.; Esplin, E.D.; Nussbaum, R.L.; Sartor, O. Prevalence
of Germline Variants in Prostate Cancer and Implications for Current Genetic Testing Guidelines. JAMA Oncol. 2019, 5, 523.
[CrossRef]
Omura, S.; Tanaka, H.; Koyama, Y.; Oiwa, R.; Katagiri, M.; Awaya, J.; Nagai, T.; Hata, T. Nanaomycins A and B*, New Antibiotics
Produced by a Strain of Streptomyces. J. Antibiot. 1974, 27, 363–365. [CrossRef]
Tanaka, H.; Marumo, H.; Nagai, T.; Okada, M.; Taniguchi, K. Nanaomycins, New Antibiotics Produced by a Strain of Streptomyces.
III. A New Component, Nanaomycin C, and Biological Activities of Nanaomycin Derivatives. J. Antibiot. 1975, 28, 925–930.
[CrossRef] [PubMed]
Kasai, M.; Shirahata, K.; Ishii, S.; Mineura, K.; Marumo, H.; Tanaka, H.; Omura, S. Structure of Nanaomycin E, a New Nanaomycin.
J. Antibiot. 1979, 32, 442–445. [CrossRef]
Cancers 2023, 15, 2684
14.
15.
16.
17.
18.
19.
20.
21.
22.
23.
24.
25.
26.
27.
28.
29.
30.
31.
32.
33.
34.
35.
36.
37.
12 of 13
Matsuo, H.; Nakanishi, J.; Noguchi, Y.; Kitagawa, K.; Shigemura, K.; Sunazuka, T.; Takahashi, Y.; Omura,
S.; Nakashima, T.
Nanaomycin K, a New Epithelial–Mesenchymal Transition Inhibitor Produced by the Actinomycete “Streptomyces Rosa Subsp.
Notoensis” OS-3966. J. Biosci. Bioeng. 2020, 129, 291–295. [CrossRef]
Kitagawa, K.; Shigemura, K.; Ishii, A.; Nakashima, T.; Matsuo, H.; Takahashi, Y.; Omura, S.; Nakanishi, J.; Fujisawa, M.
Nanaomycin K Inhibited Epithelial Mesenchymal Transition and Tumor Growth in Bladder Cancer Cells in Vitro and in Vivo. Sci.
Rep. 2021, 11, 9217. [CrossRef] [PubMed]
Kitagawa, K.; Shigemura, K.; Sung, S.-Y.; Chen, K.-C.; Huang, C.-C.; Chiang, Y.-T.; Liu, M.-C.; Huang, T.-W.; Yamamichi, F.;
Shirakawa, T.; et al. Possible Correlation of Sonic Hedgehog Signaling with Epithelial–Mesenchymal Transition in Muscle-Invasive
Bladder Cancer Progression. J. Cancer Res. Clin. Oncol. 2019, 145, 2261–2271. [CrossRef] [PubMed]
Kawata, M.; Koinuma, D.; Ogami, T.; Umezawa, K.; Iwata, C.; Watabe, T.; Miyazono, K. TGF-β-Induced EpithelialMesenchymal Transition of A549 Lung Adenocarcinoma Cells Is Enhanced by pro-Inflammatory Cytokines Derived from RAW
264.7 Macrophage Cells. J. Biochem. 2012, 151, 205–216. [CrossRef]
Morikawa, M.; Derynck, R.; Miyazono, K. TGF-β and the TGF-β Family: Context-Dependent Roles in Cell and Tissue Physiology.
Cold Spring Harb. Perspect. Biol. 2016, 8, a021873. [CrossRef]
Sun, D.-Y.; Wu, J.-Q.; He, Z.-H.; He, M.-F.; Sun, H.-B. Cancer-Associated Fibroblast Regulate Proliferation and Migration of
Prostate Cancer Cells through TGF-β Signaling Pathway. Life Sci. 2019, 235, 116791. [CrossRef]
Gilbert, S.; Péant, B.; Mes-Masson, A.-M.; Saad, F. IKKε Inhibitor Amlexanox Promotes Olaparib Sensitivity through the
C/EBP-β-Mediated Transcription of Rad51 in Castrate-Resistant Prostate Cancer. Cancers 2022, 14, 3684. [CrossRef]
Takahashi, K.; Akatsu, Y.; Podyma-Inoue, K.A.; Matsumoto, T.; Takahashi, H.; Yoshimatsu, Y.; Koinuma, D.; Shirouzu, M.;
Miyazono, K.; Watabe, T. Targeting All Transforming Growth Factor-β Isoforms with an Fc Chimeric Receptor Impairs Tumor
Growth and Angiogenesis of Oral Squamous Cell Cancer. J. Biol. Chem. 2020, 295, 12559–12572. [CrossRef] [PubMed]
Huang, G.; Osmulski, P.A.; Bouamar, H.; Mahalingam, D.; Lin, C.-L.; Liss, M.A.; Kumar, A.P.; Chen, C.-L.; Thompson, I.M.; Sun,
L.-Z.; et al. TGF-β Signal Rewiring Sustains Epithelial-Mesenchymal Transition of Circulating Tumor Cells in Prostate Cancer
Xenograft Hosts. Oncotarget 2016, 7, 77124–77137. [CrossRef] [PubMed]
Thiery, J.P.; Acloque, H.; Huang, R.Y.J.; Nieto, M.A. Epithelial-Mesenchymal Transitions in Development and Disease. Cell 2009,
139, 871–890. [CrossRef] [PubMed]
Wang, M.; Ren, D.; Guo, W.; Huang, S.; Wang, Z.; Li, Q.; Du, H.; Song, L.; Peng, X. N-Cadherin Promotes Epithelial-Mesenchymal
Transition and Cancer Stem Cell-like Traits via ErbB Signaling in Prostate Cancer Cells. Int. J. Oncol. 2016, 48, 595–606. [CrossRef]
[PubMed]
Satelli, A.; Li, S. Vimentin as a Potential Molecular Target in Cancer Therapy Or Vimentin, an Overview and Its Potential as a
Molecular Target for Cancer Therapy. Cell. Mol. Life Sci. 2011, 68, 3033–3046. [CrossRef]
Liu, Y.-N.; Abou-Kheir, W.; Yin, J.J.; Fang, L.; Hynes, P.; Casey, O.; Hu, D.; Wan, Y.; Seng, V.; Sheppard-Tillman, H.; et al. Critical
and Reciprocal Regulation of KLF4 and SLUG in Transforming Growth Factor β-Initiated Prostate Cancer Epithelial-Mesenchymal
Transition. Mol. Cell. Biol. 2012, 32, 941–953. [CrossRef]
Zhang, L.; Zhou, F.; Dijke, P. ten Signaling Interplay between Transforming Growth Factor-β Receptor and PI3K/AKT Pathways
in Cancer. Trends Biochem. Sci. 2013, 38, 612–620. [CrossRef]
Yang, J.; Nie, J.; Ma, X.; Wei, Y.; Peng, Y.; Wei, X. Targeting PI3K in Cancer: Mechanisms and Advances in Clinical Trials. Mol.
Cancer 2019, 18, 26. [CrossRef]
Shorning, B.Y.; Dass, M.S.; Smalley, M.J.; Pearson, H.B. The PI3K-AKT-MTOR Pathway and Prostate Cancer: At the Crossroads of
AR, MAPK, and WNT Signaling. Int. J. Mol. Sci. 2020, 21, 4507. [CrossRef]
Liu, Z.; Zhu, G.; Getzenberg, R.H.; Veltri, R.W. The Upregulation of PI3K/Akt and MAP Kinase Pathways Is Associated with
Resistance of Microtubule-Targeting Drugs in Prostate Cancer. J. Cell. Biochem. 2015, 116, 1341–1349. [CrossRef]
Park, S.; Kwon, W.; Park, J.-K.; Baek, S.-M.; Lee, S.-W.; Cho, G.-J.; Ha, Y.-S.; Lee, J.N.; Kwon, T.G.; Kim, M.O.; et al. Suppression of
Cathepsin a Inhibits Growth, Migration, and Invasion by Inhibiting the P38 MAPK Signaling Pathway in Prostate Cancer. Arch.
Biochem. Biophys. 2020, 688, 108407. [CrossRef] [PubMed]
Dhillon, A.S.; Hagan, S.; Rath, O.; Kolch, W. MAP Kinase Signalling Pathways in Cancer. Oncogene 2007, 26, 3279–3290. [CrossRef]
[PubMed]
Strittmatter, B.G.; Jerde, T.J.; Hollenhorst, P.C. Ras/ERK and PI3K/AKT Signaling Differentially Regulate Oncogenic ERG
Mediated Transcription in Prostate Cells. PLoS Genet. 2021, 17, e1009708. [CrossRef] [PubMed]
Lin, S.-R.; Mokgautsi, N.; Liu, Y.-N. Ras and Wnt Interaction Contribute in Prostate Cancer Bone Metastasis. Molecules 2020, 25,
2380. [CrossRef]
Nickols, N.G.; Nazarian, R.; Zhao, S.G.; Tan, V.; Uzunangelov, V.; Xia, Z.; Baertsch, R.; Neeman, E.; Gao, A.C.; Thomas, G.V.; et al.
MEK-ERK Signaling Is a Therapeutic Target in Metastatic Castration Resistant Prostate Cancer. Prostate Cancer Prostatic Dis. 2019,
22, 531–538. [CrossRef]
Ismy, J.; Sugandi, S.; Rachmadi, D.; Hardjowijoto, S.; Mustafa, A. The Effect of Exogenous Superoxide Dismutase (SOD) on
Caspase-3 Activation and Apoptosis Induction in Pc-3 Prostate Cancer Cells. Res. Rep. Urol. 2020, 12, 503–508. [CrossRef]
O’Neill, A.J.; Boran, S.A.; O’Keane, C.; Coffey, R.N.T.; Hegarty, N.J.; Hegarty, P.; Gaffney, E.F.; Fitzpatrick, J.M.; Watson, R.W.G.
Caspase 3 Expression in Benign Prostatic Hyperplasia and Prostate Carcinoma. Prostate 2001, 47, 183–188. [CrossRef]
Cancers 2023, 15, 2684
38.
39.
40.
41.
42.
13 of 13
Rizzo, M. Mechanisms of Docetaxel Resistance in Prostate Cancer: The Key Role Played by MiRNAs. Biochim. Et Biophys. Acta
(BBA) Rev. Cancer 2021, 1875, 188481. [CrossRef]
Singh, A.; Settleman, J. EMT, Cancer Stem Cells and Drug Resistance: An Emerging Axis of Evil in the War on Cancer. Oncogene
2010, 29, 4741–4751. [CrossRef]
Hanrahan, K.; O’Neill, A.; Prencipe, M.; Bugler, J.; Murphy, L.; Fabre, A.; Puhr, M.; Culig, Z.; Murphy, K.; Watson, R.W. The Role
of Epithelial–Mesenchymal Transition Drivers ZEB1 and ZEB2 in Mediating Docetaxel-resistant Prostate Cancer. Mol. Oncol.
2017, 11, 251–265. [CrossRef]
Ren, J.; Chen, Y.; Song, H.; Chen, L.; Wang, R. Inhibition of ZEB1 Reverses EMT and Chemoresistance in Docetaxel-Resistant
Human Lung Adenocarcinoma Cell Line. J. Cell. Biochem. 2013, 114, 1395–1403. [CrossRef] [PubMed]
Yoneda, T.; Kunimura, N.; Kitagawa, K.; Fukui, Y.; Saito, H.; Narikiyo, K.; Ishiko, M.; Otsuki, N.; Nibu, K.; Fujisawa, M.; et al.
Overexpression of SOCS3 Mediated by Adenovirus Vector in Mouse and Human Castration-Resistant Prostate Cancer Cells
Increases the Sensitivity to NK Cells in Vitro and in Vivo. Cancer Gene 2019, 26, 388–399. [CrossRef] [PubMed]
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual
author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to
people or property resulting from any ideas, methods, instructions or products referred to in the content.
...
論文の公開元へ
